Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis.
New Approaches in the Design and Development of Cannabinoid Receptor Ligands: Multifunctional and Bivalent Compounds.
Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters.
Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation.
Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis.
Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale.
JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?
Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.
Low vitamin D level is associated with higher relapse rate in natalizumab treated MS patients.
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
Treatment of Neuropathic Pain and Functional Limitations Associated With Multiple Sclerosis Using an MRI-Compatible Spinal Cord Stimulator: A Case Report With Two Year Follow-Up and Literature Review.
Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.
Saffold Virus Type 3 (SAFV-3) Persists in HeLa Cells.
A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis.
Procedural Variations in the Stroop and the Symbol Digit Modalities Test: Impact on Patients with Multiple Sclerosis.
Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
Transplantation of Fas-deficient or wild-type neural stem/progenitor cells (NPCs) is equally efficient in treating experimental autoimmune encephalomyelitis (EAE).
Astrocyte loss and astrogliosis in neuroinflammatory disorders.
Erythrocyte membrane Fatty acids in multiple sclerosis patients and hot-nature dietary intervention with co-supplemented hemp-seed and evening-primrose oils.
Trunk muscle activity during walking in persons with multiple sclerosis: The influence of body weight support.
Prolactin Is Not Required for the Development of Severe Chronic Experimental Autoimmune Encephalomyelitis.
AAV1.NT-3 gene therapy for Charcot-Marie-Tooth neuropathy.
Natalizumab in the pediatric MS population: results of the Italian registry.
Building an RNA Sequencing Transcriptome of the Central Nervous System.
The Synergistic Local Immunosuppressive Effects of Neural Stem Cells Expressing Indoleamine 2,3-Dioxygenase (IDO) in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model.
Pages
« first
‹ previous
…
291
292
293
294
295
296
297
298
299
…
next ›
last »